A Walk in the PARP: Therapeutic Strategies Targeting DNA Repair Defects in Prostate Cancer
  • CME

Watch this CME-certified on-demand Webcast of a CCO symposium at ASCO GU 2019 to gain expert perspectives on the evolving role of PARP inhibitors in advanced prostate cancer, including an overview of BRCA and other DNA repair deficiencies, guidance on genetic testing, review of the latest clinical data, and a panel case discussion.
Celestia Higano Headshot
Celestia S. Higano, MD, FACP
David A. Quigley, PhD
Charles J. Ryan, MD
Physicians: maximum of 1.0 AMA PRA Category 1 Credit
Released: March 20, 2019 Expiration: March 19, 2020

Learning Objectives

Upon completion of this activity, participants should be able to:
  • Describe the rationale and process for assessing germline and somatic DNA repair pathway alterations in prostate cancer
  • Examine the mechanism of PARP inhibition to achieve “synthetic lethality” in prostate cancer with deficient DNA damage response
  • Evaluate the available clinical evidence for the use of PARP inhibitors to treat metastatic CRPC harboring BRCA1/2 or other DNA damage response mutations
  • Identify patients suitable for enrollment on ongoing clinical studies investigating PARP inhibitor monotherapy or in combination with other agents in prostate cancer

Information on this Educational Activity

Clinical Care Options, LLC (CCO) requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose any relevant conflict of interest (COI) they may have as related to the content of this activity. All identified COI are thoroughly vetted and resolved according to CCO policy. CCO is committed to providing its learners with high-quality CME/CE activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of a commercial interest.

The faculty reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME/CE activity:

Faculty

Celestia S. Higano, MD, FACP

Professor 
Departments of Medicine and Urology
University of Washington
Seattle, Washington

Celestia (Tia) S. Higano, MD, FACP, has disclosed that she has received consulting fees from Astellas, Bayer, Blue Earth Diagnostics, Clovis Oncology, Ferring, Hinova, Janssen, Myriad Genetics, Orion Corporation, and Tolmar and that her partner/spouse has been employed in a leadership position by and has ownership interest in CTI Biopharma.
David A. Quigley, PhD

Assistant Adjunct Professor
Department of Epidemiology and Biostatistics
Helen Diller Family Comprehensive Cancer Center
University of California, San Francisco
San Francisco, California

David A. Quigley, PhD, has no real or apparent conflicts of interest to report.
Charles J. Ryan, MD

Professor of Medicine
B.J. Kennedy Chair in Clinical Medical Oncology
Director,
 Division of Hematology, Oncology and Transplantation
Department of Medicine
University of Minnesota
Oncologist
Division of Hematology, Oncology and Transplantation
University of Minnesota Health Clinics and Surgery Center
Minneapolis, Minnesota

Charles J. Ryan, MD, has disclosed that he has received consulting fees from Bayer, Clovis Oncology, Janssen, and Sanofi Genzyme; has received funds for research support from Clovis Oncology and the Prostate Cancer Foundation; has received fees for non-CME/CE services from Janssen; and has served in a study leadership position for Clovis Oncology.

Staff

Rachael M. Andrie, PhD

Scientific Director

Rachael M. Andrie, PhD, has no real or apparent conflicts of interest to report.
Timothy A. Quill, PhD

Associate Director, Scientific Services

Timothy A. Quill, PhD, has no real or apparent conflicts of interest to report.
Kevin Obholz, PhD

Senior Director, Educational Strategy

Kevin Obholz, PhD, has no real or apparent conflicts of interest to report.
Gordon Kelley

Senior Clinical Editor

Gordon Kelley has no real or apparent conflicts of interest to report.
Megan Cartwright, PhD

Senior Clinical Editor

Megan Cartwright, PhD, has no real or apparent conflicts of interest to report.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Target Audience

This program is intended for oncologists and urologists and other healthcare providers who care for patients with prostate cancer.

Goal

The goal of this activity is to improve participants’ knowledge of, confidence in, and competence in integrating PARP inhibitors into the treatment of patients with prostate cancer.

Physician Continuing Medical Education

Joint Accreditation Statement

In support of improving patient care, Clinical Care Options, LLC (CCO) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Designation of Credit

CCO designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Program Medium

This program has been made available online.

Instructions for Credit

Participation in this self-study activity should be completed in approximately 1.0 hours. To successfully complete this activity and receive credit, participants must follow these steps during the period from March 20, 2019, through March 19, 2020:

1. Register online at http://www.clinicaloptions.com.
2. Read the target audience, learning objectives, and faculty disclosures.
3. Study the educational activity online or printed out.
4. Submit answers to the posttest questions and evaluation questions online.

You must receive a test score of at least 65% and respond to all evaluation questions to receive a certificate. After submitting the evaluation, you may access your online certificate by selecting the certificate link on the posttest confirmation page. Records of all CME/CE activities completed can be found on the "CME/CE Manager" page. There are no costs/fees for this activity.

Related Content

In this Clinical Care Options (CCO) slideset, Dr. Elizabeth R. Plimack provides insights on managing adverse events and treatment options for advanced RCC after previous therapy

Elizabeth R. Plimack, MD, MS Released: February 13, 2020

In this Clinical Care Options (CCO) slideset, Dr. Martin H. Voss provides insights on the use of first-line systemic therapy for intermediate-risk/poor-risk RCC

Martin H. Voss, MD Released: February 13, 2020

In this Clinical Care Options (CCO) slideset, Dr. M. Dror Michaelson provides insights on the use of first-line systemic therapy for favorable-risk RCC

M. Dror Michaelson, MD, PhD Released: February 13, 2020

CME-certified Webcast of a CCO symposium at SITC 2019 featuring expert perspectives on optimal integration of immunotherapy into care of patients with bladder cancer

Elizabeth R. Plimack, MD, MS
Program Director
Matthew Galsky, MD
Physicians: maximum of 1.0 AMA PRA Category 1 Credit Released: January 23, 2020 Expiration: January 22, 2021
Provided by Clinical Care Options, LLC

Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA

Sophia Kelley
(203)-316-2125
skelley@clinicaloptions.com
www.clinicaloptions.com

Supported by educational grants from
AstraZeneca
Clovis Oncology
Pfizer Inc.

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue

Welcome to the CCO site.

You are accessing CCO's educational content today as a Guest user.

If you would like to continue with free, full access to the CCO Web sites, including free CME/CE credits, please click the button below.

Continue

More info

CCO’s educational programs are available completely free of charge on the ClinicalOptions.com, inPractice.com, and inPracticeAfrica.com Web sites. Certain features and functions are restricted for Guest users. By consenting to become a full member, you are eligible to receive CME/CE credit or participation certificates from certified activities, to register for CCO’s free live meetings and webinars, and to receive CCO’s email newsletters alerting you to new content. You can unsubscribe from our emails at any time. CCO strictly protects the privacy of our members, according to our privacy policy.

A confirmation email will be sent to . Not You?